Amarantus Bioscience Holdings Inc (AMBS)

[lewsogge]

Honestly his estimates are nothing more than pure speculation just like ours. What I was referring to is this quote of yours:

The bio-tech analyst predicted PPS of .20 when they reach revenue of 40 mil. in 2027.

He values the company at $42,000,000 right now. Says it bold and clear. That also doesn't include ANY of the diagnostic's $800,000,000 potential revenue up for grabs, somewhere around 2016 by his estimates. Again, I don't agree with his timeframes (we shall see when Gerald announces next steps moving forward following data EOM)... Regardless, with MANF alone, Jason is claiming AMBS' market value should be $42 mill right now. Currently, with our PPS and SS, our market value is $15.5 million. A $42 million market cap would be .19 PPS. Add on top of that whatever his magical crystal ball tells him AMBS is worth for their diagnostics, and its looking like a nice multi-bagger of an investment once the market corrects itself.

That means both products could be on the market by 2016 and generating revenues to the diagnostic division. Management believes both products are a $300 to $500 million revenue opportunity. Amarantus is planning to spin off these assets to form a new company and dividend the shares to shareholders. We intend to focus on Amarantus Diagnostics with a third article. However, our preliminary "back-of-the-envelop" calculations for LymPro and NuroPro eclipse the valuation for MANF. That's presents interesting upside for current investors.